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Summary Serum CA19-9 levels have been measured in 34 patients with asymptomatic colorectal cancer, 39
age and sex matched subjects with healthy colons (as assessed at full colonoscopy) and 55 patients known to
have liver metastases from primary colorectal cancers. In subjects with asymptomatic cancer the median
CAl9-9 was 12.75 U ml- (0.0-280.7 Uml-), in the healthy controls the median CAl9-9 was 12.80 Uml-
(0.0-88.9 Uml') and in those with liver metastases was 62.5 U ml1 (4.8-458.0 U ml'). Levels were
significantly higher in patients with metastatic disease than in patients with asymptomatic tumours or the
healthy controls, however there was no significant difference between the asymptomatic group and the
controls. Using an upper limit of normal of 37 U ml-', the sensitivity of CAI9-9 was 60.3% for the detection
of colorectal cancer with liver metastases but only 17.6% for asymptomatic cancer. Serum CA19-9 estimation
is of no value as a means of screening for asymptomatic colorectal cancer.
In 1979 Koprowski et al. described a monoclonal antibody,
116NS 19-9 (CA19-9), raised against a human colorectal
cancer cell line.
Elevated serum levels of this antigen have been described
in association with a range of gastrointestinal malignancies
including colorectal carcinoma (Del Villano et al., 1983;
Koprowski et al., 1981), and it has been suggested that it
may be useful in the diagnosis and monitoring of patients
with colorectal carcinoma (Sears et al., 1982).
Experience of other serum tumour markers, in particular
carcinoembryonic antigen, suggests that elevated levels are
most often associated with a large tumour bulk; to be of
value as a screening agent serum levels must be elevated in
asymptomatic patients, typically with a small tumour mass.
We have therefore examined serum CA19-9 levels in
asymptomatic patients undergoing investigation of positive
faecal occult blood tests in an ongoing screening study. It is
known that such individuals will comprise a group harbour-
ing asymptomatic colorectal cancer and a group who are
shown to have normal colons as assessed at colonoscopy. We
have also examined a cohort of consecutive patients known
to have extensive liver metastases from colorectal primaries.
Method
Patients
Serum samples were obtained prior to colonoscopy in asymp-
tomatic subjects (50-75 years of age) attending a designated
clinic having had positive Haemoccult ('faecal occult blood)
tests in the Nottingham Colorectal Cancer Screening Study
(Hardcastle et al., 1989).
All subjects subsequently underwent colonoscopy following
a Picolax bowel preparation. Serum samples were then retro-
spectively assayed for CA19-9 in 34 consecutive subjects
shown to have colorectal carcinoma, and in 39 consecutive
subjects with healthy colons as assessed by colonoscopy,
these have now been followed up for a minimum period of
18 months and all remain well.
Serum CA19-9 was also measured in 55 patients, known to
have liver metastases, attending a designed colorectal cancer
follow-up clinic.
CA19-9
The CA19-9 antigen was quantitated using an established
commercially available, assay, ELSA-CA19-9 (Cis bioindus-
tries Compagnie ORIS Industries S.A. France). The recom-
mended level of 37 U ml-' was taken as the upper limit of
normal.
Statistical comparisons have been by the Mann-Whitney
test, the Chi squared test, and Fisher's Exact Test.
Results
The median CAI9-9 levels in patients with metastatic liver
disease was 62.50 U ml-' (range 4.8-458.0 U ml', inter-
quantile range 20.5-222.0 U ml-') (Figure 1). In the 34
patients shown to have asymptomatic carcinoma (16 stage A,
8 stage B, 7 stage C, 3 stage D) the median CAI9-9 level was
12.75 U ml' (range 0.00-280 U ml', interquantile range
6.00-16.47 U ml-') and in patients with normal colons was
12.80 U ml-' (range 0.00-88.9 U ml-', interquantile range
8.10-19.80 U ml-').
The levels in those with metastatic disease were signifi-
cantly higher than those in people with asymptomatic cancers
and healthy controls (Mann-Whitney, P<0.001 and P<,
0.001 respectively), however there was no difference in levels
between those with asymptomatic cancers and controls
(Mann-Whitney P = 0.7).
Taking the usual upper limit of normal of 37 U ml-',
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Figure 1 Serum CAI9-9 in healthy controls and patients with
metastatic and asymptomatic colorectal cancer (Median and
interquartile range).
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elevated serum CA19-9 levels were present in 35 (60.3%) of
those with liver metastases compared to 6 (17.6%) of the
patients with asymptomatic cancer (x2= 17.9, df= 1, P =
<0.001). Three (7.7%) of those with healthy colons had
elevated levels, a lower proportion than those with liver
metastases (X2 = 27.4, df= 1, P = <0.001). There was no
significant difference in the number of people with asymp-
tomatic cancer and normal controls with elevated serum
CA19-9 levels (Fisher's Test P=0.2).
CAI9-9 levels in relation to tumour stage is given in Figure
2. Six (25%) of the patients with asymptomatic Stage A or B
tumours had serum CA19-9 levels greater than 37 U ml-'. In
the smaller cohort with asymptomatic Stage C or D cancers
none had CA19-9 levels greater than 37 U ml-'.
Of the 39 asymptomatic subjects shown to be free of
colorectal carcinoma, 36 had CA19-9 levels below 37 U ml1',
a specificity of the test for cancer of 92.3%.
Discussion
In common with other tumour associated antigens it appears
that elevated serum levels of CA19-9 are normally associated
with advanced colorectal carcinoma.
In the symptomatic group with metastases in this study all
had unresectable hepatic disease with multiple deposits
throughout the liver, it is probable that the significantly
elevated CA19-9 levels in this group reflect the increased
tumour bulk present.
Of more relevance to the potential use of CA19-9 as a
screening test is the comparison of serum levels in individuals
with asymptomatic carcinoma and patients with normal col-
ons. It is evident that there is no distinction in levels seen in
the cohort with cancer and the healthy controls, a sensitivity
of 17.6% (upper limit of normal of 37 U ml-') is unaccept-
able.
Kuusela et al. (1984), measured CA19-9 in patients with
symptomatic colorectal carcinoma, they found that levels
were elevated (>37 U ml-') in 47% of patients with Dukes
Stage C or D cancers, but in only one of 26 patients with a
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Figure 2 Serum CA19-9 in asymptomatic cancer - Tumour
Stage (Median and interquartile range).
symptomatic Dukes Stage A or B cancer; overall the sensi-
tivity of CA19-9 for symptomatic cancers was 36%.
In our study the specificity of the test for cancer was
92.3%, whilst at first inspection this may seem satisfactory,
in the context of mass population screening a specificity as
low as this is unacceptable: it is known that the specificity of
faecal occult blood screening using the Haemoccult test is
greater than 98% (Hardcastle et al., 1989; Kronberg et al.,
1989), a percentage drop in specificity would result in an
increase of many thousands of individuals requiring further
investigation if applied in a mass population screening pro-
gramme.
Despite being raised initially against a colorectal cell line it
appears that the main role of CA19-9 is in the detection and
monitoring of malignancy at sites other than colorectum;
whereas there may be a place for CAl9-9 in monitoring
subjects with advanced colorectal malignancy there is no
justification for its use as a means of identifying asympto-
matic colorectal malignancy.
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